- recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
This study is testing an experimental gene therapy, AVB-101, for a specific type of Frontotemporal Dementia (FTD-GRN). It aims to see if AVB-101 is safe and can help improve levels of a certain protein in the brain for people aged 30-75.
United States · Belgium · Canada - active not recruitingPHASE1, PHASE2
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
This study is testing a new gene therapy called PBFT02 for a type of dementia called Frontotemporal Dementia (FTD). It aims to see if PBFT02 is safe, well-tolerated, and can help people with FTD caused by specific gene problems (GRN or C9ORF72 mutations).
United States · Australia · Brazil - enrolling by invitation
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
This study aims to understand serious conditions like ALS and similar diseases better. By looking at genes, symptoms, and biological markers, researchers hope to find new ways to develop treatments. People with these conditions and their families are invited to take part.
United States · Germany · South Africa - active not recruitingPHASE1, PHASE2
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
This study is testing a new medicine, LY3884963, for Frontotemporal Dementia (FTD) caused by a specific gene change. It will check if the medicine is safe, how it affects a protein called progranulin, and if it helps patients.
United States · Australia · Belgium - recruiting
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
This study looks into how certain brain cells, called tanycytes, might be involved in Alzheimer's disease and a similar condition called frontotemporal dementia. Researchers want to see if how these cells handle a hormone called leptin changes early in these diseases.
France - active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This study is testing a new medicine called DNL593 for frontotemporal dementia (FTD-GRN). It aims to see if it's safe, how the body handles it, and if it helps people with this specific type of dementia, compared to a dummy drug.
United States · Belgium · Brazil